Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Mar 2;73(4):62. doi: 10.1007/s00262-024-03652-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — Evaluating the effect of tumor immune infiltration and tumor purity on the drug sensitivity of ZA based on patients with HCC in TCGA and ICGC datasets. A The flowchart of data research. TCGA-LIHC (n = 373), ICGC-LICA-JP (n = 231), and ICGC-LICA-FR (n = 161) were included into analyses. The ESTIMATE score and tumor purity were first calculated. B Boxplots showed the patient with HCC who had higher degree of immune infiltration had significantly higher ESTIMATE score and lower tumor purity in TCGA-LIHC cohort(****, p < 0.0001). C The boxplot showed prediction of the drug sensitivity in TCGA-LIHC cohort. The value of IC50 were lower in stage I and stage II than stage III (*, p < 0.05). D Boxplots showed the values of IC50 were lower in HCC patients with high immunogenicity (TCGA-LIHC ****, p < 0.0001; ICGC-JP ***, p < 0.001; ICGC-FR *p < 0.05)